Onward Therapeutics S.A.

Onward Therapeutics is a development stage oncology company, focusing on the identification and development of innovative medicines for the treatment of cancer. The company, led by an experienced team in drug development, adopts a ‘Buy and Build’ business model of acquiring licenses for potential development candidates and investing in their partners with platform technologies. The company is based at Biopôle (a life sciences campus in Epalinges), near Lausanne, Switzerland and also operates fromParis, France and Taipei, Taiwan. *

	Start	2021-02-16 existent
	Industry	BIOTECH
	Industry 2	cancer drug

	Region	Epalinges VD
	Country	Switzerland
	Street	4 Route de la Corniche Biopôle, Phenyl Building
	City	1066 Epalinges VD
		Address record changed: 2021-02-17

Basic data	Employees	n. a.

		* Document for »About Section«: Biomunex Pharmaceuticals SASU. (2/16/21). "Press Release: Biomunex Pharmaceuticals Signs Strategic License and Co-Development Agreement with Onward Therapeutics for Proprietary Bispecific Antibody Program". Paris & Cambridge, MA.

		Record changed: 2023-07-10

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Onward Therapeutics S.A.

[1] Biomunex Pharmaceuticals SASU. (2/16/21). "Press Release: Biomunex Pharmaceuticals Signs Strategic License and Co-Development Agreement with Onward Therapeutics for Proprietary Bispecific Antibody Program". Paris & Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]